These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19666869)

  • 1. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
    Kosmider O; Gelsi-Boyer V; Cheok M; Grabar S; Della-Valle V; Picard F; Viguié F; Quesnel B; Beyne-Rauzy O; Solary E; Vey N; Hunault-Berger M; Fenaux P; Mansat-De Mas V; Delabesse E; Guardiola P; Lacombe C; Vainchenker W; Preudhomme C; Dreyfus F; Bernard OA; Birnbaum D; Fontenay M;
    Blood; 2009 Oct; 114(15):3285-91. PubMed ID: 19666869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
    Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
    Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis.
    Lin Y; Lin Z; Cheng K; Fang Z; Li Z; Luo Y; Xu B
    Oncotarget; 2017 Jun; 8(26):43295-43305. PubMed ID: 28476038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
    Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
    Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
    Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
    Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
    BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
    Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired mutations in TET2 are common in myelodysplastic syndromes.
    Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
    Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
    Gu S; Xia J; Tian Y; Zi J; Ge Z
    BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Coltro G; Antelo G; Lasho TL; Finke CM; Pardanani A; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Fernandez-Zapico ME; Robertson KD; Bosi A; Vannucchi AM; Tefferi A; Patnaik MM
    Am J Hematol; 2020 Apr; 95(4):E86-E89. PubMed ID: 31925810
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
    Santamaría C; Ramos F; Puig N; Barragán E; de Paz R; Pedro C; Insunza A; Tormo M; Del Cañizo C; Diez-Campelo M; Xicoy B; Salido E; Sánchez del Real J; Hernández M; Chillón C; Sanz GF; García-Sanz R; San Miguel JF; González M
    Ann Hematol; 2012 Dec; 91(12):1887-95. PubMed ID: 22875062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.
    Gurnari C; Pagliuca S; Guan Y; Adema V; Hershberger CE; Ni Y; Awada H; Kongkiatkamon S; Zawit M; Coutinho DF; Zalcberg IR; Ahn JS; Kim HJ; Kim DDH; Minden MD; Jansen JH; Meggendorfer M; Haferlach C; Jha BK; Haferlach T; Maciejewski JP; Visconte V
    Blood Adv; 2022 Jan; 6(1):100-107. PubMed ID: 34768283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.